Pembrolizumab monotherapy has shown robust and durable antitumour activity and promising survival data in both locally advanced and recurrent/metastatic cutaneous SCC, according to an Australian oncologist. Speaking at the American Association for Cancer Research (AACR) meeting, Dr Brett Hughes presented an interim analysis of Keynote-629 – a first analysis of the local advanced cohort and ...
Pembrolizumab monotherapy effective in cSCC
By Mardi Chapman
4 May 2021